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Sepsis is a serious medical problem and constitutes an 
enormous burden for health care systems. A recent meta-
analysis published in Critical Care [1] evaluated clinical 
eﬀ   ects of colony-stimulating factors in patients with 
severe sepsis/septic shock. Here, the results will be 
discussed in the context of the available data.
A large body of evidence indicates that the early ‘hyper-
inﬂ   ammatory’ phase in sepsis is often followed by a 
persistent ‘hypo-inﬂ  ammation’ with severe alterations in 
both innate and cellular immunity [2-5]. Findings during 
this state of ‘sepsis-associated immunosuppression’ in-
clude diminished phagocytotic activity, cytokine expres-
sion proﬁ  le changes towards an anti-inﬂ  ammatory pheno-
type, increased expression of negative (co-)stimu  latory 
molecules, reduced monocytic antigen presenta  tion via 
the major histocompatibility (MHC) class II complex 
(mHLA-DR), dysfunction and apoptosis of lymphocytes, 
and upregulation of regulatory T cells [2-7]. Mounting 
data show that patients with persistent ‘sepsis-associated 
immunosuppression’ are at increased risk for nosocomial 
infections [8], prolonged ICU stay, and death [4,9]. 
Typically, these patients will be resuscitated success  fully 
in the early shock phase, will then develop an ‘anergic’ 
immunological state, and will ﬁ  nally succumb to repeated 
infections from rather avirulent secondary pathogens.
Keeping this in mind, immunostimulation in sepsis 
seems tempting but only few trials have investigated the 
immunological and clinical eﬀ   ects of immune recon-
struc  tive therapies [4-6,10]. Such approaches include 
immuno  stimulation with interferon-γ [11], selective extra-
corporeal reduction of immunodepressants [12], and 
medication with granulocyte-colony stimulating factor 
(G-CSF)/granulocyte-macrophage colony stimulating 
factor (GM-CSF) (summarized in [1]) . However, when 
analysing the available data on CSF therapy in sepsis, it 
seems impor  tant that G-CSF and GM-CSF have distinct 
properties. Both are potent immunostimulators, induce 
leukocytosis, augment the activity of granulocytes and 
have anti-infectious (mostly anti-bacterial) capabilities. 
GM-CSF additionally stimulates monocytes/macro  phages, 
induces monocytic cytokine expression (for example, 
tumor necrosis factor-α, interferon-γ) and induces 
antigen presentation (mHLA-DR) [13].
As demonstrated in the recent meta-analysis [1], a total 
of 12 placebo-controlled randomized controlled trials 
(RCTs; n = 2,380 patients) investigated the clinical eﬀ  ects 
of G-CSF (n = 8 RCTs) and GM-CSF (n = 4 RCTs) in 
patients with severe sepsis/septic shock. Th  e main out-
come measure of this sytematic review was all-cause 
short-term (14-day; data from n = 138 patients available) 
and 28-day mortality. No signiﬁ  cant diﬀ  erence in 28-day 
mortality (relative risk (RR) 0.93, 95% conﬁ  dence interval 
(CI) 0.79 to 1.11, P = 0.44) and in-hospital mortality 
(RR 0.97, 95% CI 0.69 to 1.36, P = 0.86) was observed 
when patients receiving G-CSF or GM-CSF were 
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© 2011 BioMed Central Ltdcompared to placebo-treated controls. Analysis of G-CSF 
(n = 2,044, 6 RCTs) or GM-CSF (n = 89, 3 RCTs) treat-
ment subgroups revealed no 28-day mortality beneﬁ  t. In 
line with previous ﬁ  ndings from non-randomized trials, 
CSF therapy appeard safe. Nevertheless, although an 
eﬀ  ect on mortality was not observed, the meta-analysis 
identiﬁ   ed that patients receiving G-CSF or GM-CSF 
therapy have a signiﬁ   cantly increased rate of reversal 
from infection (RR 1.34, 95% CI 1.11 to 1.62, P = 0.002). 
Although this ﬁ  nding is mainly based on available G-CSF 
data, it supports earlier ﬁ  ndings from animal models that 
CSF therapy may indeed induce a faster reversal from 
infection. Th   is seems especially the case in pneumogenic 
sepsis [14]. In line with data from animal models and 
G-CSF trials, we recently demonstrated in the ﬁ  rst 
biomarker-guided immunostimulatory placebo-controlled 
RCT in sepsis that GM-CSF therapy signiﬁ  cantly 
shortens the time of mechanical ventilation [15].
However, a number of limitations of the meta-analysis 
need to be discussed. First, a combined G-CSF/GM-CSF 
analysis might be challenged due to the distinct biology 
and underlying treatment concepts of each. Whereas G-
CSF is typically given to increase antimicrobial defense 
via numerical induction of granulocytes, GM-CSF 
therapy aims to re-stimulate antigen-presenting cell 
function/adaptive immunity. Moreover, as G-CSF is often 
applied in induction-chemotherapy-induced neutro-
penia, the role of neutropenia-related sepsis in the 
included trials remains unclear. Second, the heterogeneity 
of the trials under investigation is noteworthy as the trials 
diﬀ  ered greatly in regard to applied CSF doses, routes of 
adminis  tration, pharmacological CSF subtypes and 
patient characteristics (for example, disease severity). 
Th   is certainly constrains data comparability. Th  ird,  most 
trials did not stratify study patients according to their 
immuno  logical state and the eﬃ     cacy of the immuno-
logical inter  vention was not tested or reported. We 
believe that this remains a prerequisite for future 
immuno  modulatory trials in sepsis. Although assessment 
of the underlying complex immunological condition 
using a single bio  marker may be regarded as challenging, 
standardized quantitative tests (for example, ﬂ  ow-cyto-
metric mHLA-DR assessment) were recently developed 
that may both serve as global biomarkers for cellular 
immunity and help to guide future immunotherapies 
[7,10,16].
Future trials on CSF therapy should be performed in 
immunologically stratiﬁ   ed patients and concomitant 
immune monitoring seems mandatory. As CSF therapy 
seems to contribute to a faster reversal of infection and 
may shorten the time of mechanical ventilation, there is 
an urgent need for larger RCTs adequately powered for 
28-day mortality, respective surrogates, or reduction of 
nosocomial infection rates. Currently, on the basis of the 
limited heterogenous data available, a mortality beneﬁ  t 
for CSF therapy cannot be demonstrated. At this point in 
time, CSF therapy should thus be applied in the context 
of clinical trials only, with the exception being individual 
oﬀ  -label rescue approaches.
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